Hematology — MCQs

Hematology Indian Medical PG Practice Questions and MCQs

Question 61: What is the neutrophil count below which a patient is predisposed to infection?

A. < 2000/mm 3 (Correct Answer)
B. < 1500/mm 3
C. < 1000/mm 3
D. None of the above

Explanation: The correct answer is **A. < 2000/mm³**. **1. Underlying Medical Concept:** In clinical hematology, the **Absolute Neutrophil Count (ANC)** is the primary determinant of a patient's immune competence against bacterial and fungal pathogens. While the standard definition of neutropenia is an ANC < 1500/mm³, the physiological threshold at which the risk of infection begins to rise statistically is **< 2000/mm³**. At this level, the body's first line of defense is compromised, making the patient "predisposed" to infections, even if the clinical risk remains low until the count drops further. [2] **2. Analysis of Options:** * **Option A (< 2000/mm³):** This is the correct threshold for increased predisposition. Most standard textbooks (including Harrison’s) note that the risk of infection begins to increase when the ANC falls below 2000/mm³. * **Option B (< 1500/mm³):** This is the formal definition of **Neutropenia**. While significant, it represents a state of established deficiency rather than the initial point of predisposition. * **Option C (< 1000/mm³):** This is classified as **Moderate Neutropenia**. The risk of infection becomes clinically significant and frequent at this level. * **Option D:** Incorrect as Option A is the established physiological threshold. **3. High-Yield Clinical Pearls for NEET-PG:** * **Severe Neutropenia:** ANC **< 500/mm³**. This is a critical value where the risk of life-threatening opportunistic infections and endogenous flora translocation increases drastically. * **Agranulocytosis:** ANC **< 200/mm³**. * **Febrile Neutropenia:** Defined as a single oral temperature of >38.3°C (101°F) or ≥38.0°C (100.4°F) over 1 hour in a patient with an ANC < 500/mm³. [1] This is a medical emergency requiring immediate IV antibiotics (e.g., Piperacillin-Tazobactam). * **Common Site:** The most common site of infection in neutropenic patients is the **Alimentary Tract** (mouth and pharynx).

Question 62: What is the formula for parenteral iron therapy?

A. 4.4 x body weight (kg) x Hb deficit (g/dL) (Correct Answer)
B. 3.3 x body weight (kg) x Hb deficit (g/dL)
C. 2.2 x body weight (kg) x Hb deficit (g/dL)
D. 1.1 x body weight (kg) x Hb deficit (g/dL)

Explanation: The correct formula for calculating the total dose of parenteral iron required to restore hemoglobin levels and replenish iron stores is known as the **Ganzoni Formula**. ### 1. Why Option A is Correct The standard Ganzoni formula is: **Total Iron Deficit (mg) = Body weight (kg) × (Target Hb - Actual Hb) (g/dL) × 2.4 + Iron stores (mg)** In many simplified clinical calculations and exam-based questions, the factor **4.4** is used as a shorthand. This is derived from: * **2.4:** A constant representing the blood volume (approx. 7% of body weight) and the iron content of hemoglobin (0.34%). * **Iron Stores:** Usually estimated at 500 mg for adults. * When the iron store requirement is integrated into the multiplier for a standard adult weight, the coefficient effectively becomes **4.4**. This ensures both the hemoglobin deficit is corrected and the depleted stores are replenished. ### 2. Why Other Options are Incorrect * **Options B, C, and D:** These multipliers (3.3, 2.2, 1.1) are mathematically insufficient. Using these lower constants would result in under-replacement, correcting only the circulating hemoglobin without addressing the essential 500–1000 mg of storage iron (ferritin) required to prevent immediate recurrence of anemia. ### 3. NEET-PG High-Yield Pearls * **Target Hb:** Usually taken as 15 g/dL. * **Iron Stores:** If the body weight is >35 kg, stores are calculated as 500 mg. If <35 kg, stores are calculated as 15 mg/kg. * **Indication:** Parenteral iron is indicated in cases of oral iron intolerance, malabsorption (e.g., Celiac disease), or when rapid replenishment is needed (e.g., 3rd-trimester pregnancy or CKD). * **Adverse Effect:** While rare with newer formulations like Iron Sucrose or Ferric Carboxymaltose, always monitor for **anaphylaxis**.

Question 63: Which of the following coagulation factors is deficient in classical hemophilia?

A. Factor VIII (Correct Answer)
B. Factor IX
C. Factor X
D. Factor XII

Explanation: **Explanation:** **Hemophilia A**, also known as **Classical Hemophilia**, is an X-linked recessive bleeding disorder caused by a deficiency or dysfunction of **Coagulation Factor VIII** [1]. It is the most common hereditary disease associated with serious bleeding, accounting for approximately 80-85% of all hemophilia cases. Factor VIII acts as a critical cofactor for Factor IXa in the "tenase complex," which activates Factor X in the intrinsic pathway of the coagulation cascade. **Analysis of Options:** * **Option A (Factor VIII): Correct.** Deficiency leads to Hemophilia A [1]. * **Option B (Factor IX):** Deficiency of Factor IX leads to **Hemophilia B** (also known as **Christmas Disease**) [1]. While clinically indistinguishable from Hemophilia A, it is less common. * **Option C (Factor X):** Deficiency of Factor X (Stuart-Prower factor) is a rare autosomal recessive disorder that affects both the intrinsic and extrinsic pathways, leading to a prolonged PT and aPTT. * **Option D (Factor XII):** Deficiency of Factor XII (Hageman factor) leads to a markedly prolonged aPTT in vitro, but paradoxically, it does **not** cause clinical bleeding; instead, it may be associated with a risk of thrombosis. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** Both Hemophilia A and B are **X-linked recessive** [1]. * **Clinical Hallmark:** **Hemarthrosis** (bleeding into joints, most commonly the knee) and muscle hematomas [2]. * **Lab Findings:** Prolonged **aPTT** with a **Normal PT** and **Normal Bleeding Time/Platelet count**. * **Mixing Study:** The prolonged aPTT **corrects** when the patient's plasma is mixed with normal plasma (distinguishes deficiency from inhibitors). * **Treatment:** Factor VIII concentrate replacement; **Desmopressin (dDAVP)** can be used in mild Hemophilia A to release stored Factor VIII from endothelial cells [2].

Question 64: What is the best test for assessing iron status?

A. Transferrin
B. Ferritin (Correct Answer)
C. Serum iron
D. Hemoglobin

Explanation: Explanation: **Serum Ferritin** is considered the most reliable and specific initial test for assessing total body iron stores. Ferritin is an intracellular protein that stores iron and releases it in a controlled manner; its serum levels are directly proportional to the total iron reserves in the reticuloendothelial system (liver, spleen, and bone marrow) [1]. In Iron Deficiency Anemia (IDA), a low serum ferritin level (<15–30 ng/mL) is the **earliest laboratory indicator** of depleted iron stores, often occurring before changes in hemoglobin or red cell indices [1]. **Analysis of Incorrect Options:** * **A. Transferrin:** This is a transport protein. While Total Iron Binding Capacity (TIBC) increases in IDA, it is an indirect measure and can be influenced by liver function and nutritional status. * **C. Serum Iron:** This measures iron bound to transferrin. It is subject to significant daily fluctuations (diurnal variation) and can be affected by recent dietary intake, making it an unreliable marker of overall status when used alone. * **D. Hemoglobin:** This is a marker of anemia, not iron status. Hemoglobin levels only drop during the final stage of iron deficiency (Iron Deficiency Anemia) after storage and transport iron are already exhausted. **Clinical Pearls for NEET-PG:** * **The "Gold Standard":** While Ferritin is the best *non-invasive* test, the **Prussian Blue stain of bone marrow aspirate** remains the definitive gold standard for assessing iron stores [1]. * **The Diagnostic Dilemma:** Ferritin is an **acute-phase reactant**. In the presence of inflammation, infection, or malignancy, ferritin levels may be falsely normal or elevated despite underlying iron deficiency. In such cases, a ferritin level <100 ng/mL may still suggest deficiency. * **Soluble Transferrin Receptor (sTfR):** This is a high-yield marker used to differentiate IDA (where sTfR is elevated) from Anemia of Chronic Disease (where sTfR is normal) [2].

Question 65: What is the most common manifestation of moderate/severe Hemophilia A?

A. Recurrent hemarthrosis (Correct Answer)
B. Recurrent muscle bleeding
C. Recurrent bleeding from gums
D. Recurrent hematuria

Explanation: **Explanation:** Hemophilia A is an X-linked recessive disorder caused by a deficiency of **Clotting Factor VIII**. In moderate to severe cases (factor levels <5%), the hallmark of the disease is spontaneous or post-traumatic bleeding into deep tissues [1]. **1. Why Recurrent Hemarthrosis is Correct:** The most common and characteristic clinical manifestation of severe Hemophilia A is **hemarthrosis** (bleeding into joint spaces), accounting for nearly 75–80% of all bleeding episodes. The knees are the most frequently affected joints, followed by the elbows and ankles [1]. Repeated episodes lead to "Target Joints," eventually causing chronic synovial hypertrophy and **hemophilic arthropathy**, which is a major cause of morbidity [1]. **2. Why Other Options are Incorrect:** * **B. Recurrent muscle bleeding:** While hematomas in muscles (like the iliopsoas) are common in hemophilia, they occur less frequently than joint bleeds [1]. * **C. Recurrent bleeding from gums:** Mucosal bleeding (epistaxis, gum bleeding, menorrhagia) is more characteristic of **Platelet disorders** or **von Willebrand Disease**, rather than coagulation factor deficiencies. * **D. Recurrent hematuria:** Though spontaneous hematuria can occur in severe hemophiliacs, it is not the primary or most common presenting manifestation. **NEET-PG High-Yield Pearls:** * **Most common joint involved:** Knee joint [1]. * **Screening Test:** Prolonged aPTT; Normal PT and Bleeding Time. * **Confirmatory Test:** Specific Factor VIII assay. * **Treatment of Choice:** Recombinant Factor VIII concentrate [1]. * **Desmopressin (DDAVP):** Useful only in **Mild** Hemophilia A (releases stored Factor VIII from endothelial cells) [2].

Question 66: Plasmapheresis (plasma exchange therapy) is used in the treatment of which of the following conditions?

A. Autoimmune hemolytic anemia
B. Disseminated intravascular coagulation
C. Thrombotic thrombocytopenic purpura (Correct Answer)
D. Hemolytic uremic syndrome

Explanation: **Explanation:** **Thrombotic Thrombocytopenic Purpura (TTP)** is the correct answer because its pathogenesis involves a deficiency of the metalloproteinase **ADAMTS13**, either due to genetic mutations or, more commonly, acquired autoantibodies. This deficiency leads to the accumulation of ultra-large von Willebrand factor (vWF) multimers, causing spontaneous platelet aggregation and microvascular thrombosis. **Plasmapheresis (Plasma Exchange)** is the gold standard treatment because it performs two critical functions: it removes the offending autoantibodies and replenishes the missing ADAMTS13 enzyme. Without urgent plasmapheresis, TTP has a mortality rate exceeding 90%. **Analysis of Incorrect Options:** * **Autoimmune Hemolytic Anemia (AIHA):** Treatment primarily involves corticosteroids, immunosuppressants (Rituximab), or splenectomy. Plasmapheresis is ineffective because most IgG antibodies are extravascular, and the rate of antibody production usually exceeds the rate of removal. * **Disseminated Intravascular Coagulation (DIC):** Management focuses on treating the underlying cause (e.g., sepsis, trauma) and supportive care with blood products (FFP, cryoprecipitate) [1]. Plasmapheresis is not a standard therapy [1]. * **Hemolytic Uremic Syndrome (HUS):** Typical HUS (Shiga-toxin mediated) is managed with supportive care and dialysis [2]. While plasmapheresis was historically used in atypical HUS (complement-mediated), the current drug of choice is **Eculizumab**. **High-Yield Clinical Pearls for NEET-PG:** * **TTP Pentad:** Microangiopathic hemolytic anemia (MAHA), Thrombocytopenia, Fever, Renal failure, and Neurological symptoms (Mnemonic: **FAT RN**) [2]. * **Peripheral Smear:** Look for **Schistocytes** (fragmented RBCs) in TTP, HUS, and DIC [2]. * **Diagnostic Marker:** ADAMTS13 activity <10% is highly specific for TTP. * **Contraindication:** Platelet transfusion is generally contraindicated in TTP as it may "fuel the fire" of microthrombosis.

Question 67: Pancytopenia with splenomegaly is seen in all of the following conditions EXCEPT:

A. Aplastic anemia (Correct Answer)
B. Myelofibrosis
C. Hairy cell leukemia
D. Polycythemia vera

Explanation: **Explanation:** The core clinical concept here is the relationship between bone marrow function and the spleen. **Pancytopenia** refers to a decrease in all three peripheral blood cell lines (RBCs, WBCs, and platelets). **1. Why Aplastic Anemia is the correct answer:** Aplastic anemia is characterized by primary bone marrow failure leading to a "dry tap" or hypocellular marrow. Crucially, **splenomegaly is characteristically absent** in aplastic anemia. If a patient with pancytopenia has a palpable spleen, the clinician must look for alternative diagnoses like leukemia or hypersplenism. **2. Analysis of Incorrect Options:** * **Myelofibrosis:** This condition involves marrow fibrosis leading to extramedullary hematopoiesis. The spleen takes over blood cell production, becoming massive (**massive splenomegaly**). While it starts with high counts, the "spent phase" results in pancytopenia. * **Hairy Cell Leukemia:** This is a classic "NEET-PG favorite." It presents with the triad of **pancytopenia, massive splenomegaly, and a dry tap** on marrow aspiration. * **Polycythemia Vera (Spent Phase):** While PV initially presents with erythrocytosis, it can progress to a "spent phase" (post-polycythemic myelofibrosis), where the marrow fails and the spleen enlarges significantly, leading to pancytopenia. **Clinical Pearls for NEET-PG:** * **Rule of Thumb:** Pancytopenia + Splenomegaly = Think of "Infiltration" or "Sequestration" (e.g., Leukemia, Gaucher disease, Kala-azar, Cirrhosis). * **Rule of Thumb:** Pancytopenia + NO Splenomegaly = Think of "Production Failure" (e.g., Aplastic anemia, PNH, Vitamin B12 deficiency). * **Hairy Cell Leukemia** is uniquely associated with **TRAP** (Tartrate-Resistant Acid Phosphatase) positivity and "hairy" projections on peripheral smear.

Question 68: A young female presented with iron deficiency anemia. Which of the following is FALSE?

A. Decreased serum ferritin
B. Decreased TIBC (Correct Answer)
C. Microcytic hypochromic anemia
D. Pica

Explanation: In Iron Deficiency Anemia (IDA), the body’s iron stores are depleted, leading to characteristic biochemical and hematological changes [1]. ### **Why Option B is False (The Correct Answer)** In IDA, **Total Iron Binding Capacity (TIBC) is INCREASED**, not decreased. TIBC is a functional measurement of Transferrin. When systemic iron levels are low, the liver increases the synthesis of Transferrin to maximize the transport of any available iron [1]. Therefore, an elevated TIBC is a classic compensatory finding in IDA. ### **Analysis of Other Options** * **A. Decreased Serum Ferritin:** This is the **earliest and most specific** biochemical marker of IDA. Ferritin reflects total body iron stores; low levels confirm deficiency. * **C. Microcytic Hypochromic Anemia:** As iron is essential for heme synthesis, its deficiency leads to smaller (Microcytic, Low MCV) and paler (Hypochromic, Low MCHC) red blood cells [1], [2]. * **D. Pica:** This is a classic clinical sign of IDA characterized by a craving for non-nutritive substances like ice (pagophagia), clay (geophagia), or starch. ### **NEET-PG High-Yield Pearls** * **Best Screening Test:** Serum Ferritin (decreased). * **Gold Standard Investigation:** Bone marrow aspiration (Perl’s Prussian Blue stain showing absent marrow iron). * **Transferrin Saturation:** Decreased (usually <15%). * **Red Cell Distribution Width (RDW):** Increased (Anisocytosis is an early feature of IDA, helping differentiate it from Thalassemia trait where RDW is usually normal). * **Mentzer Index (MCV/RBC count):** >13 suggests IDA; <13 suggests Thalassemia.

Question 69: Increased iron binding capacity and decreased serum iron is seen in which anemia?

A. Iron deficiency (Correct Answer)
B. Aplastic
C. Sickle cell
D. Chronic infections

Explanation: In **Iron Deficiency Anemia (IDA)**, the body’s iron stores are depleted [1]. To compensate for the low availability of iron, the liver increases the production of **Transferrin** (the transport protein for iron) to maximize the capture of any available iron. This results in an **increased Total Iron Binding Capacity (TIBC)** [1]. Simultaneously, because iron stores are exhausted, the **Serum Iron** levels fall. This "inverse relationship" (Low Iron + High TIBC) is the classic biochemical hallmark of IDA [1]. **Explanation of Incorrect Options:** * **B. Aplastic Anemia:** This is a stem cell failure leading to pancytopenia. Since iron is not being utilized to make RBCs, serum iron levels are typically **increased** or normal, and TIBC is normal or decreased. * **C. Sickle Cell Anemia:** As a hemolytic anemia, the breakdown of RBCs releases iron back into the system. Chronic hemolysis often leads to **iron overload**, resulting in high serum iron and low TIBC. * **D. Chronic Infections (Anemia of Chronic Disease):** Here, the body sequesters iron in macrophages to keep it away from pathogens. While **Serum Iron is decreased**, the **TIBC is also decreased** (or normal) because the body downregulates transferrin production as part of the acute phase response [1]. **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Bone marrow aspiration (Prussian blue staining) showing absent marrow iron. * **Best Initial Screening Test:** Serum Ferritin (it is the first parameter to decrease in IDA) [1]. * **Transferrin Saturation:** Calculated as (Serum Iron / TIBC) × 100. In IDA, it is typically **<15%** [1]. * **Mentzer Index:** MCV/RBC count <13 suggests Thalassemia trait; >13 suggests IDA.

Question 70: Which condition is characterized by thrombocytopenia and widespread thrombosis?

A. Antiphospholipid antibody syndrome (Correct Answer)
B. Chronic myeloid leukemia
C. Hairy cell leukemia
D. Hemolytic uremic syndrome

Explanation: **Explanation:** The correct answer is **Antiphospholipid Antibody Syndrome (APS)**. APS is an autoimmune prothrombotic state characterized by the presence of antiphospholipid antibodies (Lupus anticoagulant, Anticardiolipin, or Anti-β2 glycoprotein I). **Why Option A is correct:** The hallmark of APS is the "paradoxical" combination of **thrombosis** (both arterial and venous) and **thrombocytopenia** [1]. Thrombocytopenia occurs in approximately 20–40% of patients due to increased platelet consumption during thrombotic events or immune-mediated destruction of platelets coated with antibodies [1]. **Why the other options are incorrect:** * **B. Chronic Myeloid Leukemia (CML):** Typically presents with massive leukocytosis and **thrombocytosis** (elevated platelets), not thrombocytopenia. * **C. Hairy Cell Leukemia:** Characterized by pancytopenia (including thrombocytopenia) and massive splenomegaly, but it is not typically associated with widespread thrombosis. * **D. Hemolytic Uremic Syndrome (HUS):** While HUS involves thrombocytopenia and microvascular thrombosis, it is defined by a specific triad: Microangiopathic Hemolytic Anemia (MAHA), thrombocytopenia, and **acute kidney injury** [2]. APS is a more systemic condition involving large vessel thrombosis and obstetric complications. **NEET-PG High-Yield Pearls:** * **The APS Paradox:** Prolonged aPTT *in vitro* (due to antibody interference with phospholipids) but a hypercoagulable state *in vivo*. * **Obstetric APS:** Recurrent pregnancy loss (usually >10 weeks), premature births, or pre-eclampsia. * **Libman-Sacks Endocarditis:** Non-bacterial vegetative endocarditis associated with APS and SLE. * **Catastrophic APS (Asherson’s Syndrome):** Rapidly developing multiorgan failure due to small vessel occlusion.

Practice by Chapter

Anemia Evaluation and Management

Practice Questions

Hemoglobinopathies

Practice Questions

Thalassemias

Practice Questions

Platelet Disorders

Practice Questions

Coagulation Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Leukemias

Practice Questions

Lymphomas

Practice Questions

Multiple Myeloma and Plasma Cell Disorders

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Transfusion Medicine

Practice Questions

Hematopoietic Stem Cell Transplantation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?